Table 5.

Multivariate logistic regression analysis of clinical management of chemotherapy regimens with GSTP1 c.313A>G, ABCB1 c.1236C>T, and ABCB1 c.3435C>T

	Dose reduction		Dose delay		Treatment interruptiona
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
GSTP1 c.313A>G
AA	Reference		Reference		Reference
AG	0.70 (0.28–1.57)	0.36	0.35 (0.13–0.90)	0.03	0.35 (0.10–1.23)	0.10
GG	0.31 (0.09–1.03)	0.06	0.43 (0.13–1.46)	0.18	0.60 (0.14–2.58)	0.49
Dominant (AA vs. AG + GG)	0.54 (0.25–1.16)	0.12	0.36 (0.16–0.85)	0.02	0.42 (0.15–1.20)	0.11
Recessive (AA + AG vs. GG)	0.38 (0.13–1.16)	0.08	0.68 (0.22–2.12)	0.51	0.93 (0.23–3.73)	0.92
ABCB1 c.1236C>T
CC	Reference		Reference		Reference
CT	1.14 (0.36–3.64)	0.82	1.00 (0.28–3.54)	0.99	1.42 (0.28–7.26)	0.67
TT	3.33 (0.57––19.49)	0.18	1.54 (0.24–9.71)	0.64	2.03 (0.20–21.07)	0.55
Dominant (CC vs. CT + TT)	1.16 (0.39–3.45)	0.78	1.08 (0.32–3.63)	0.90	1.60 (0.32–7.90)	0.57
Recessive (CC + CT vs. TT)	3.08 (0.66–14.34)	0.15	1.71 (0.38–7.63)	0.48	1.73 (0.27–11.18)	0.56
ABCB1 c.3435C>T
CC	Reference		Reference		Reference
CT	0.89 (0.28–2.77)	0.84	1.80 (0.51–6.31)	0.36	1.70 (0.34–8.44)	0.51
TT	0.51 (0.07–3.42)	0.49	0.96 (0.12–7.69)	0.98	1.12 (0.07–15.90)	0.93
Dominant (CC vs. CT + TT)	0.95 (0.32–2.83)	0.92	1.67 (0.48–5.79)	0.42	1.55 (0.31–7.75)	0.59
Recessive (CC + CT vs. TT)	0.52 (0.10 2.68)	0.43	0.52 (0.09–2.83)	0.45	0.63 (0.07–5.50)	0.68

CI, Confidence interval; OR, odds ratio.

Odds ratios was adjusted for age, histological subtypes, and International Federation of Gynecology and Obstetrics (FIGO); category bold values indicate statistically significant differences.

^aCases of permanent discontinuation of the originally prescribed standard chemotherapy protocol (carboplatin and paclitaxel) or one of chemotherapeutic drug.